Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERACLE: Pemetrexed vs Bevacizumab Maintenance in NSCLC
NCT01303926Phase 3Unknown
- Sponsor
- Gruppo Oncologico dell'Italia Meridionale
- Start
- Jan 2010
- Primary completion
- Jun 2012
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Cisplatin + Pemetrexed -> Pemetrexed with Carboplatin + Paclitaxel + Bevacizumab -> Bevacizumab (2 arms). Primary endpoint: Difference in Quality of Life (EQ-5D). Status: unknown.
02
Drugs
pemetrexedbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01303926.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01303926.